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OBSERVATIONS ON THE GASTROINTESTINAL ADMINISTRATION
OF BOVINE SPLENIC, RENAL AND MUSCLE HOMOGENATES
ON HEMATOPOIESIS IN MAN
A PRELIMINARY REPORT

RAYMOND W . MONTO, M.D.*; JAMES A. BARRON, M . D . * *
AND JOHN W . REBUCK, M.D.,

PH.D.***

T H E SPLEEN HAS been an organ of mystery and controversy since the beginning of
medicine.' The influence of the spleen upon maturation and release of the bone
marrow elements continues to be the subject of intensive investigation. The concept
of hypersplenism as well as the role of the spleen and auto-immune disease is now
well documented. Instances of "hyposplenism" have not been recognized. Hence,
there still remains the question of a stimulatory, as well as an inhibitory, infiuence
of the spleen in hematopoietic and auto-immune syndromes.
In 1956 Jacobson observed that shielding the spleen or the intravenous injection
of splenic homogenates offered protection against the exposure of x-ray radiation in
animals.^ Berliner, in 1961, described a patient with hemorrhagic thrombocythemia
successfully treated with raw spleen administered orally in the amount of 100 gm.
daily.^ Crosby, in 1962, found that after splenectomy rats developed lasting thrombocytosis and leukocytosis of moderate degrees. When these animals were placed on
a diet of raw spleen, the white cell and platelet counts were promptiy suppressed and
remained so until the diet was returned to regular laboratory chow. Control animals
with spleens intact developed leukopenia and thrombocytopenia on a diet of raw spleen.''
A number of organs, including glandular tissues, have been studied in relation to
hematopoiesis.' The kidney is considered an important factor in the production of
erythropoietin, but a product of this organ or other sources is not available for
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human application.' This report constitutes preliminary observations

upon a group

of patients w i t h a variety of hematologic disorders who received fresh bovine spleen,
kidney and muscle homogenate via an intragastric tube.
METHODS

Fresh, whole, bovine spleen was obtained the raorning of the kill from a slaughter
house and transported on ice. The organs averaged 700 gm. in weight. The spleens were
trimmed of fat, large vessels and a raajor portion of the peritoneal covering. "The average
triramed spleen weighed approximately 500 to 600 gm. Figure 1 represents an imprint of
fresh bovine spleen. The organs were processed twice through a conventional hamburgertype grinder. "The ground spleen was then passed through a food mill which produced a
horaogenate, consisting of pardculate raatter with only a few reraaining intact cells. During
the process of horaogenization, the raaterial was cooled and diluted with 5 per cent glucose
in water. Figure 2 demonstrates the findings of a stained smear of the final product
showing particle size and an occasional intact nucleus.
The final homogenate was bottled in liter glass flasks which contained approximately
500 gra. of fresh spleen in 500 cc. of 5 per cent glucose in water. The final product was
kept under refrigeration and, in raost instances, adrainistered within 48 hours. On occasion,
frozen material was employed when the fresh product was not available.
Biochemical analysis of the splenic horaogenate showed it to contain about 5 per cent
protein and 700 rag. per cent total lipid. The electrophoresis of the homogenate deraonstrated the majority of the soluble protein to appear in the betaglobulin range.
Kidney and lean muscle were obtained 24 hr. after the kill and prepared by the sarae
raethod and in similar concentration.
A fine polyethlene tube was passed through the patient's nose and the tip placed in
the storaach. This tubing was then connected to the Barron Food Purap and operated at
speed #3 or #4. Approxiraately 1000 gm. of fresh bovine spleen, kidney and rauscle were

mm;
\

2
Figure 1

Figure 2

Imprints of fresh bovine spleen XI100.

Final splenic homogenate XI100.
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adrainistered daily during a period of 10-12 hr. Gastrointesfinal intolerance was rare and
coraplications consisted of an occasional loose bowel raovement or tendency towards fecal
irapaction. The patients were perraitted to eat regular raeals i f they desired, but. in raost
subjects, the appedte was inhibited.
Prior to the administration of the horaogenate, appropriate blood counts, bone marrow
sraears and sections were obtained which were repeated at intervals. Serura urea nitrogen
(SUN) and uric acid levels were determined every two days.
RESULTS

A total of 11 patients received 17 feedings. Fourteen were splenic homogenates,
two were kidney and one beef muscle.
CASE 1 — Diagnosis: Factor I X deficiency (plasma thromboplastin component). White,
male, aged 28 yrs., wgt., 73 kilo.
The patient did not demonstrate signs or syraptons of active disease and served as a
"control", A thousand gra. of the spleen homogenate were adrainistered daily for ten days.
During this tirae the red blood cell increased from 4.2 rail, to 4.69 rail, and the hemoglobin from 14.3 gm. to 15 gm. per cent. The white blood cell count was unchanged. The
reticulocytes increased from 1.5 per cent to 3.4 per cent. The hematocrit before onset of
therapy was 43 per cent and after 10 days 45 per cent. On the 5th day of therapy the
platelet count increased to a level of 387,000 per cu. ram. from an original determination
of 232,000. The thrombocytosis was transient and returned to 277,000 by the 10th day.
SUN rose frora 14 mg. per cent to 20 mg. per cent. The original serura uric acid blood
level was 3.4 rag. per cent and on the 10th day rose to 10.2 rag. per cent. While the coaguladon tiraes did not improve significantly during the treatment, the plasma clotnng tirae
decreased from 416 seconds to 355 seconds; the prothrombin dme frora 19 seconds to 17
seconds; and the prothrombin consumption from 16.3 seconds to 18 seconds. The 2 stage
prothrombin determination before therapy was 129 units and after therapy 210 units. A t a
later date this patient received 1000 gra. of beef homogenate daily for 8 days without
alteration of the peripheral blood count, uric acid, or coagulation studies.
CASE 2 — Diagnosis: Multiple sclerosis, advanced, with paraplegia, severe chronic cystitis
and pyelonephritis, raultiple deep decubitus ulcers, associated with raalnutrition, "control".
White, raale, aged 34 yrs., wgt., 43 kilo.
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Before administraticn of splenic homogenate the patient had been on a homogenized
regular hospital diet fed intragastrically. The initial course of therapy consisted of 500 gm. of
splenic homogenate without apparent hematologic response or increase in SUN or uric acid
(Chart I ) . The feeding was increased to 1000 gm. per day and on the 7th day the platelet
count rose frora an original level of 212.000 per cu. rara. to 377.000. The uric acid level at
cnset was 6.4 rag. per cent. There were no significant alterations of the white or red
cell count. The serura electrophoresis was not altered during this course of tharepy. While
receiving 1000 gm. of splenic homogenate a day, the uric acid level reached 12.9 rag. per
cent by the 10th day.
Later this same individual was administered 800 cc. of the splenic supernatent obtained
by high-speed centrifugation of the total homogenate (Chart I I ) . The platelet count rose
from an original level of 240,000 per cu. rara. to 550.000 on the l l t h day of therapy. Only
minimal increases in serum uric acid levels were encountered. Subsequently, the thawed
frozen sediraent of the splenic homogenate obtained from the previous centrifugation was
given to the patient in the araount of 800 gm. daily (Chart I I ) . There was noted no .significant alteration of the blood platelet count, and the maximura uric acid level reached was
10 rag. per cent on the 4th day of therapy. After an interval of 7 days this individual received 1(100 gm. of homogenized bovine kidney over a 14 day period. Aside frora minor
increase in reticulocyte count frora 2.4 per cent to 4.1 per cent and an elevation of uric acid
from 3.8 mg. par cent to 5.8 mg. per cent, there were no significant aherations of the red
and white cell count or blood platelets.
CASE 3 — Diagnosis: Hypoplastic anemia, severe. White female, aged 80 yrs., wgt., 51 kilo.
ilie patient was severely pancytopenic with generalized bleeding phenomena related to
extreme thrombocytopenia. The original course of therapy consisted of 500 gm. of splenic
homogenate daily for nine days. The peripheral blood elements did not change significantly.
The blood uric acid level rose from initial 2 mg. per cent to 5.3 mg. per cent. A second
course of therapy consisted of 1000 gm. of splenic homogenate daily. Hemoglobin and red
cell response could not be ascertained for reason of intermittent bleeding and transfusion need.
A white blood cell count rose from 2.400 to 5.300 per cu mm. No significant change occurred
in the circulating blood platelets. The blood uric acid level reached 6.8 mg. per cent on the
8th day. The raost striking effect was seen in this patient's bone marrow .section before
therapy (Figure 3), and after corapletion of therapy (Figure 4 ) .
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Figure 3

Figure 4
Case 3 — Aspirate section of marrow after
therapy. Note return to normal cellularity except for megakaryocytes X300.

Case 3 — Aspirate section of marrow before
therapy showing aplasia X300.

CASE 4 — Diagnosis: Congenital familial erythroblastopenia (congenital hypoplastic anemia)
previously splenectomized. White, male, aged 22 yrs., wgt., 70 kilo.
This patient was complicated with severe cirrhosis, myocarditis and polyglandular insufficiency. The initial red blood cell count was 1.21 mil., hemoglobin 6.2 gm. per cent
and white blood cell count 7,900 per cu. mm. Reticulocyte count was 1 per cent and
platelet count 380,000 per cu. mm. and the heraatocrit was 18 per cent. The bone marrow
differential showed but 5.8 per cent erythroblasts (Figure ,5). The initial SUN was 16 mg.
per cent and the uric acid 2.6 rag. per cent. On the 4th day of therapy with bovine splenic
horaogenate the platelet count was elevated to 995,000. The thrombocytosis was sustained
throughout the course of therapy and graduafiy fell to pretreatment level cn completion
of feeding. The reticulocytes increased to 5.7 per cent on the 10th day with an increase
in red cell count to 1.67 m i l . and hemoglobin to 7'gm. After completing the course of feeding, the progress bone marrow was performed and erythroblasts were now 18 per cent
and the raarrow seeraed to have normal cellularity (Figure 6).'
This patient was subsequently treated with 1000 gm. daily of homogenized kidney for
13 days without significant change in the hematologic values.
CASE 5 — Diagnosis: Acute auto-iraraune thrombocytopenic purpura in steroid relapse.
White, male, aged 10 yrs., wgt., 27 kilo.
This individual did not respond to 500 gm. of splenic horaogenate in a 7 day period,
following which 1000 gm. daily was administered for six successive days. The original
platelet count was 4,000 per cu. mm. This rose to 18,000 on the 9th day of therapy. A
mild increase in the blood hemoglobin from 10.9 gm. per cent to 12 gm. per cent was
noted. The white cell count increased from 4,300 to 10,400 on the 8th day of treatment. The
reticulocyte count increased from 0.9 per cent" to 3.3 per cent in 10 days associated with
marked shift to the left in the whhe cell differential. While receiving 1000 gm. cf homogenate
daily, the uric acid levels reached 8.2 mg. per cent f r o m an original level of 3.2 mg. per
cent.
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Figure 5
Case 4 — Aspirate section of marrow before
therapy. Note boney spicule, fat cells and a
few hematopoietic cells X300.
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Figure 6
Case 4 — Aspirate section of marrow after
therapy. Note hypercellularity of marrow with
increa.se in normoblasts X300.

While the original bone raarrow showed an adequate number of megakaryocytes
(Figure 7), they were notably increased in the marrow following corapletion of the feeding (Figure 8). There was no significant alteration of the serum electrophoresis or total
protein.
CASE 6 — Diagnosis: Intermittent acute auto-imraune throrabocytopenic purpura, previously
splenectomized White, female, aged 55 yrs., wgt., 51 kilo.
This individual was markedly thrombocytopenic with levels frora 5 to 10,000 per cu.
mm. for a two month period. She had failed to respond to adrenal corticosteroids which
were discontinued. The patient received 1000 gm. of splenic horaogenate for a 13 day period.
On the 5th day of therapy the platelets had increased to 33,000. Iraproveraent continued
and a normal platelet count of 232,000 was encountered on the 14th day of therapy. She
has maintained this level. Uric acid levels reached a maximura of 9.1 mg. per cent on
the 7th day of therapy, and the SUN remained within normal lirats. There were no
significant alterations of the heraoglobin or white blood cell count. The original bone
raarrow examination revealed but few megakaryocytes in a midly hypoplastic bone marrow.
Following therapy there was an apparent increase in the number of megakaryocytes.
CASE 7 — Diagnosis: Myeloid metaplasia, agnogenic. White raale, aged 75 yrs., wgh. 54 kilo.
Hemoglobin at onset of feeding with splenic homogenate was 10.5 gm. per cent and
platelet count 32,000 per cu. mm. The patient was given intragastric splenic homogenate
1000 gra. daily for ten days. On the 10th day the heraoglobin was 12.4 gm. per cent and
platelet count 95,000. The white cell count at onset of treatment was 77,000; on the 9th
day it had fallen to 48,700 and in 15 days to 20,000. There was continued iraproveraent in
the platelet count to 102,500 on the 6th day of treatraent by feeding.
CASE 8 — Diagnosis: Hodgkin's disease with severe toxicity, pancytopenia and bone raarrow
hypoplasia. White, raale, aged 60 yrs., wgt., 70 kilo.
Patient received 1000 gra. of splenic horaogenate for a 10 day period. Before therapy
and for raany months the platelet count had ranged frora 30 to 40,000 per cu. rara. On the
4th day of intragastric administration of bovine splenic homogenate the platelet count
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Figure 7
Case 5 — Aspirate section of marrow before
therapy. Note full cellularity and numerous
megakaryocytes X300.

Figure 8
Case 5 — Aspirate section of marrow after
therapy. Note marked hyperplasia X300.

was 155,000. Nitrogen mustard, 0.2 mg. per kilo, was given on two successive days. No
gastrointestinal toxicity to the mustard occurred, and an excellent clinical response to mustard was encountered within four days. The platelet count continued to improve, reached
a maxiraum of 175,000 during hospitalization and was raaintained at a normal range of
200,000 for a period of months. During therapy the uric acid level of 11.7 mg. was encountered on the 9th day of therapy. The SUN advanced f r o m a level of 12 mg. per cent
before therapy to 29 mg. per cent on the 9th day. Following therapy these chemical values
returned to normal limits.
CASE 9 — Diagnosis: Lymphosarcoma, terminal. White, female, aged 15 yrs., wgt., 31 kilo.
Received 600 gm. of splenic homogenate daily for 3 days. On the 3rd day of therapy
the SUN rose to 94 rag. per cent from initial level of 24 mg. per cent and the uric acid from
3.6 rag. to 10.7 rag. per cent. These findings were associated with clinical signs and syraptoms of uremia, and for this reason the findings were discontinued. Within 48 hours there
was raarked clinical iraproveraent in her renal status and the SUN and uric acid returned
to near norraal levels. There were no significant changes in the peripheral blood counts.
CASE 10 — Diagnosis: Lvmphosarcoma, asyraptomatic. White, female, aged 52 yrs, wgt
50 kilo.
This patient received 1000 gra. of splenic homogenate for ten days without significant
alteration of the red cell count or the hemoglobin. The white blood cell count was 10,700
per cu. ram. at onset and on the last day of treatment was reported as 14,500. The blood
platelets before therapy were 432,000 per cu. mm., rose to 600,000 cn the 5th day of
therapy and reached a peak of 647,000 on the 9th day of therapy. After discontinuance of
the intragastric feedings the blood platelets were reduced to their pretreatment leveL
CASE 11 — Diagnosis: Nutritonal macrocytic anemia. White, female, aged 15 mo., wgt.,
7 kilo.
The patient received only two adrainistrations of intragastric bovine splenic horaogenate
in the amounts of 12 and 25 gra., respectively. For reasons of the serious clinical state of
the patient, routine therapy was then instituted.
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DISCUSSION

Numerous investigators have tested various fractions of both animal and human
spleens in relation to hematopoiesis and protection against radiation with varying
degrees of success.'"" The results of these experiences were not convincing and most
often were controversial. Both an inhibitory and a stimulatory effect upon the bone
marrow has been claimed. Failure in response to splenic material in some instances
may be related to the mode of administration, the type of homogenate or the amount
of the organ given.
The spleen is an organ with an exceedingly high nucleoprotein content. The
cellular constituants are composed largely of the nuclear material desoxyribonucleic
acid ( D N A ) and a smaller amount of ri'Donucleic acid ( R N A ) , fractions of which
some are soluble and insoluble. Speculation as to the mode of action of splenic homogenate administered gastrointestinally raises two possibilities. The material may contain
a "hormonal-like substance" capable of being absorbed by the gastrointestinal tract.
A second, and more plausible, explanation would be the absorption of degraduated
products of nucleoprotein in excess to enhance marrow function. Pisciotta" found that
during bone marrow recovery from drug induced bone marrow toxicitv, compensatory
increases in D N A and RNA were capable of overcoming the depressant action of the
drug in vivo.
Thrombocytosis with evidence of increased megakaryocytcgenesis was the most
commonly encountered hematologic response in those patients receiving bovine splenic
homogenate in this series. Case 3 and case 4 gave suggestive evidence of stimulation
of erythrocytic and granulocytic cell lines of the bone marrows. Case 8 was of interest
in view of apparent successful treatment with nitrogen mustard in the presence of
severe pancytopenia and marrow hypoplasia. In case 7 reduction of the total leukocyte
count Irom 77,000 to 20,000 per cu. mm. during the course of therapy was most
noteworthy.
This data must be interpreted in the light of the natural courses of these disease
states, together with pre- and current adjunctive therapy when indicated in the case
abstracts.
Studies are currently underway as to the efficacy of stored frozen homogenate
and supernatant fluid of the homogenate in both patients and laboratory animals.
CONCLUSIONS

1. Bovine splenic, renal and beef muscle homogenate have been administered to
patients with various hematological disorders gastrointestinally by intragastric tube in
the amounts of 1000 gm. daily, for periods of 7-14 days. This type of feeding is
well tolerated.
2. Patients receiving bovine splenic homogenates regularly demonstrate thrombocytosis and increased megakaryocytogenesis to varying degrees. In some patients there
appears to be erythroid as well as myeloid bone marrow stimulation.
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3. In one patient it was possible to administer nitrogen mustard successfully in
spite of a moderate pancytopenia and bone marrow hypoplasia.
4. Bovine renal and muscle homogenates in three patients produced no significant
hematologic alteration.
5. The data presented indicates the need for further evaluation.
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